Sign In
Buy ALLR
$1.19
-0.0300 (-2.46%)
At Close: Jul 24, 2026
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
10:41am, Wednesday, 22'nd Jul 2026
Here is how Allarity Therapeutics, Inc. (ALLR) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
08:00am, Tuesday, 07'th Jul 2026
Allarity Therapeutics is now poised to run its DRP ® testing in-house in a CLIA-certified laboratory environment The FDA requires that biomarker testing to select patients for registration trials mus
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?
10:40am, Monday, 06'th Jul 2026
Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sector so far this year.
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
08:00am, Tuesday, 30'th Jun 2026
Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP ® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or th
Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript
11:32am, Friday, 26'th Jun 2026
Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
10:41am, Friday, 19'th Jun 2026
Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited - Sponsored ADR (ATHE) have performed compared to their sector so far this year.
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
08:00am, Thursday, 18'th Jun 2026
Principal Investigator Kathleen N. Moore, M.D.
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
10:40am, Wednesday, 03'rd Jun 2026
Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their sector so far this year.
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
04:30pm, Friday, 15'th May 2026
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer - Allarity has received a Notice of Allowance for new i
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
08:45am, Friday, 08'th May 2026
TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenopar
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
08:00am, Tuesday, 05'th May 2026
Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced ovarian cancer Supports accelerating stenoparib toward FDA approv
TARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing steno
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
08:00am, Tuesday, 31'st Mar 2026
Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028 Received FDA Fast Track designation for stenoparib, en
Allarity Therapeutics (ALLR) Projected to Post Quarterly Earnings on Monday
02:14am, Monday, 23'rd Mar 2026
Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) is expected to be posting its results before the market opens on Monday, March 30th. Analysts expect Allarity Therapeutics to post earnings of ($
Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Drops By 20.7%
01:41am, Sunday, 15'th Mar 2026
Allarity Therapeutics, Inc. (NASDAQ: ALLR - Get Free Report) was the recipient of a large decline in short interest during the month of February. As of February 27th, there was short interest totaling
